Laurel Wealth Advisors Inc. Has $604,000 Position in Gilead Sciences, Inc. (GILD)

Laurel Wealth Advisors Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.6% during the first quarter, Holdings Channel reports. The institutional investor owned 8,951 shares of the biopharmaceutical company’s stock after selling 741 shares during the period. Laurel Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $604,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. West Oak Capital LLC increased its position in Gilead Sciences by 11.2% in the first quarter. West Oak Capital LLC now owns 4,634 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 467 shares in the last quarter. Fulton Bank N.A. increased its position in Gilead Sciences by 8.1% in the first quarter. Fulton Bank N.A. now owns 43,429 shares of the biopharmaceutical company’s stock valued at $2,950,000 after buying an additional 3,253 shares in the last quarter. Curbstone Financial Management Corp increased its position in Gilead Sciences by 3.8% in the first quarter. Curbstone Financial Management Corp now owns 12,520 shares of the biopharmaceutical company’s stock valued at $850,000 after buying an additional 460 shares in the last quarter. Chevy Chase Trust Holdings Inc. increased its position in Gilead Sciences by 2.2% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 1,132,792 shares of the biopharmaceutical company’s stock valued at $76,944,000 after buying an additional 24,507 shares in the last quarter. Finally, Bridges Investment Counsel Inc. increased its position in Gilead Sciences by 58.2% in the first quarter. Bridges Investment Counsel Inc. now owns 18,689 shares of the biopharmaceutical company’s stock valued at $1,269,000 after buying an additional 6,875 shares in the last quarter. 74.02% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Gilead Sciences, Inc. (GILD) traded up 0.01% on Friday, reaching $72.35. The company had a trading volume of 2,137,748 shares. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.10. The company has a market capitalization of $94.48 billion, a P/E ratio of 7.86 and a beta of 1.21. The company has a 50 day moving average of $72.57 and a 200-day moving average of $68.82.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same period in the previous year, the business earned $3.08 EPS. Analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

ILLEGAL ACTIVITY WARNING: This news story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/08/18/laurel-wealth-advisors-inc-has-604000-position-in-gilead-sciences-inc-gild.html.

Several equities analysts have recently weighed in on the company. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC reissued a “hold” rating and set a $83.00 target price on shares of Gilead Sciences in a research report on Thursday, July 27th. BMO Capital Markets reissued an “outperform” rating and set a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Deutsche Bank AG reissued a “buy” rating and set a $81.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, Cowen and Company reissued an “outperform” rating and set a $90.00 target price on shares of Gilead Sciences in a research report on Thursday, July 27th. Twelve equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $80.31.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock valued at $15,223,184 over the last ninety days. 1.30% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply